Voyager Pharmaceutical Corporation Withdraws Initial Public Offering

RALEIGH, N.C., Dec. 13 /PRNewswire/ -- Voyager Pharmaceutical Corporation announced today that, due to market conditions, it is withdrawing its Form S-1 registration statement from the Securities and Exchange Commission.

"While we have decided to withdraw our plans for an IPO at this time, we are continuing to advance the clinical development of our lead product candidate Memryte for the treatment of mild to moderate Alzheimer's disease, as well as our other clinical programs," said Patrick S. Smith, Chairman, President and CEO of Voyager Pharmaceutical Corporation.

About Voyager Pharmaceutical Corporation

Voyager Pharmaceutical Corporation is a biopharmaceutical company focused on developing drugs for diseases associated with aging and development. Voyager's scientific approach is based on the observation that many diseases of aging may be caused by changes in human reproductive hormone levels that are characteristic of the aging process. Voyager's most advanced product candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer that it is developing for the treatment of mild to moderate Alzheimer's disease. Voyager was founded in 2001 and is headquartered in Raleigh, N.C.

Contact: Patrick Smith, President and CEO

T. 919-846-4880

Voyager Pharmaceutical Corporation

CONTACT: Patrick Smith, President and CEO of Voyager PharmaceuticalCorporation, +1-919-846-4880

Back to news